AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 151 min read$OBIO

Orchestra BioMed Receives $6.1 Million Milestone Payment From Vivasure Acquisition By Haemonetics

Orchestra BioMed (OBIO) received a $6.1M milestone payment from Haemonetics (HAE) following HAE's acquisition of Vivasure. This adds to a prior $5M upfront payment, with potential for $10M more in earnouts. The funds will support OBIO's AVIM and Virtue SAB clinical trials. HAE's stock closed at $106.31, up 3.53%.

Original reporting
rttnews.com
Published Sep 15, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 4:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$OBIO
Bullish
medium confidence
Mentioned
$OBIO · $HAE
Relevance
6/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$OBIOBullishLow
01

Why it matters

The milestone payment provides additional capital for OBIO's pipeline programs.

02

Market read

Cash proceeds may support OBIO's ongoing trials and could be priced in by investors.

03

What to watch

Future earnouts could increase total proceeds if milestones are met.

Relevance 6/10Novelty 6/10Timing: payment received Sep 14, 2026

Background

Orchestra BioMed holds a strategic stake in Vivasure, which Haemonetics acquired.

Company-level read

Ticker impact

$OBIOBullishMedium confidence
Context

Orchestra BioMed received a $6.1M milestone payment from Haemonetics' acquisition of Vivasure.

Expected impact

Potential modest upside as runway extension is priced in.

Evidence & confidence

The payment is a primary disclosure but the amount is modest for a micro‑cap biotech.

Market effects

Sector

May slightly improve sentiment for small‑cap biotech cash‑flow news.

Regional

Limited to US biotech investors.

Global

Low

Counterpoint

What could challenge this read

The payment is too small to move the stock materially.

Key entities

  • Company
    Orchestra BioMed Holdings, Inc.

    Biotech firm receiving the milestone payment.

  • Company
    Haemonetics Corporation

    Acquirer of Vivasure, payer of the milestone.

Read at source← All news

Related articles

AUG 19
$HAEHighAI 8/10

Haemonetics reconnects with CSL in US plasma collection deal

Haemonetics (HAE) announced a new deal with CSL Plasma to supply its NexSys PCS platforms and apheresis kits for U.S. plasma collection centers. The contract, following FDA approval, does not have minimum purchase requirements. HAE shares rose 15% in after-hours trading, reaching $107. Analysts estimate potential revenue of $183M-$223M annually if CSL fully switches back, with a 6%-8% growth rate and 10%-20% pricing premium.

massdevice.com2 min
AUG 19
$HAEHigh

Haemonetics stock hits 52-week high at 106.64 USD

Haemonetics Corp (HAE) hit a 52-week high of $106.64, up 92.73% over a year. The medical tech firm's stock has surged 72.49% in six months and 14.57% in the past week. Q1 earnings beat estimates, with revenue at $339M. BTIG raised its price target to $96. HAE signed a supply deal with CSL Plasma.

investing.com2 min
AUG 19
$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

rttnews.com3 min
AUG 18
$HAEMedAI 8/10

Up another 16% TODAY, see why this AI-picked medtech stock is now up +92%

Haemonetics Corporation (NYSE:HAE) rose 15.9% after announcing a supply agreement with CSL Plasma, adding to its 91.88% surge since being identified by InvestingPro's AI models. The company reported Q1 2027 revenue of $339.4M and adjusted EPS of $1.14, raising its full-year revenue growth outlook to 5-8%. InvestingPro's AI-powered stock picker has identified multiple stocks with significant gains, including Haemonetics, which was highlighted for its valuation, profitability, and growth potential

investing.com7 min
AUG 18
$HAEMed

Haemonetics stock surges 16% on CSL Plasma supply deal

Haemonetics (NYSE:HAE) shares rose 16.3% after it announced a non-exclusive U.S. supply agreement with CSL Plasma. Signed Aug. 14, 2026, it allows CSL to use Haemonetics NexSys PCS devices with Persona PLUS and buy related disposables, with no minimum purchase commitments. Haemonetics did not revise fiscal 2027 guidance and plans an update at its Q2 earnings call in Nov. 2026.

investing.com4 min